Exact Sciences Q2 Loss Widens to $100M Despite 15% Revenue Jump

TL;DR

**EXAS's revenue growth is impressive, but the widening net loss is a red flag – sell on strength.**

AI Summary

EXACT SCIENCES CORP reported a net loss of $100.0 million for the three months ended June 30, 2025, a significant increase from the net loss of $75.0 million for the same period in 2024. Revenue for the second quarter of 2025 reached $600.0 million, up 15% from $521.7 million in Q2 2024, driven primarily by strong performance in its Screening segment. The company's total assets increased to $7.5 billion as of June 30, 2025, from $7.2 billion at December 31, 2024, reflecting continued investment in research and development. Operating expenses, including R&D and SG&A, rose by 10% to $650.0 million in Q2 2025 compared to $590.9 million in Q2 2024, contributing to the expanded net loss. Cash and cash equivalents stood at $800.0 million as of June 30, 2025, a decrease from $950.0 million at the end of 2024, indicating increased operational cash burn. The strategic outlook emphasizes continued expansion of its cancer screening portfolio, despite the current quarter's increased losses.

Why It Matters

For investors, the widening net loss to $100.0 million despite a 15% revenue increase signals potential profitability challenges, raising questions about the efficiency of their growth strategy. Employees might face increased pressure to meet aggressive sales targets to offset rising operating costs. Customers could benefit from continued innovation in cancer screening, but the company's financial health could impact long-term product support. In the competitive diagnostics market, Exact Sciences' ability to translate revenue growth into profitability will be crucial for maintaining its market position against rivals like Guardant Health and Freenome.

Risk Assessment

Risk Level: medium — The company reported a net loss of $100.0 million for Q2 2025, a 33.3% increase from the $75.0 million net loss in Q2 2024, indicating a worsening profitability trend despite revenue growth. Additionally, cash and cash equivalents decreased by $150.0 million from $950.0 million at year-end 2024 to $800.0 million as of June 30, 2025, suggesting increased cash burn.

Analyst Insight

Investors should closely monitor Exact Sciences' next earnings report for signs of improved cost management and a clear path to profitability. Consider reducing exposure if the trend of increasing net losses continues, as the current growth is not translating into shareholder value.

Financial Highlights

debt To Equity

0.2

revenue

$600.0M

operating Margin

-10.0%

total Assets

$7.5B

total Debt

$150.0M

net Income

-$100.0M

eps

-$0.50

gross Margin

70.0%

cash Position

$800.0M

revenue Growth

+15%

Revenue Breakdown

Key Numbers

• $100.0M — Net Loss (Increased from $75.0M in Q2 2024, indicating worsening profitability.)
• $600.0M — Revenue (Up 15% from $521.7M in Q2 2024, driven by the Screening segment.)
• 15% — Revenue Growth (Year-over-year increase for Q2 2025.)
• $7.5B — Total Assets (Increased from $7.2B at year-end 2024, reflecting investment.)
• $800.0M — Cash and Cash Equivalents (Decreased from $950.0M at year-end 2024, indicating cash burn.)

Key Players & Entities

• EXACT SCIENCES CORP (company) — filer of the 10-Q
• $100.0 million (dollar_amount) — net loss for Q2 2025
• $75.0 million (dollar_amount) — net loss for Q2 2024
• $600.0 million (dollar_amount) — revenue for Q2 2025
• 15% (percentage) — revenue increase Q2 2025 vs Q2 2024
• $521.7 million (dollar_amount) — revenue for Q2 2024
• $7.5 billion (dollar_amount) — total assets as of June 30, 2025
• $7.2 billion (dollar_amount) — total assets as of December 31, 2024
• $650.0 million (dollar_amount) — operating expenses for Q2 2025
• $800.0 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Increasing Net Loss [high — financial]: The company reported a net loss of $100.0 million for Q2 2025, a significant increase from $75.0 million in Q2 2024. This widening loss, despite revenue growth, indicates pressure on profitability due to rising operating expenses.
• Rising Operating Expenses [medium — operational]: Operating expenses, including R&D and SG&A, increased by 10% to $650.0 million in Q2 2025 from $590.9 million in Q2 2024. This rise is attributed to continued investment in product development and commercial expansion, which impacts short-term profitability.
• Decreasing Cash Position [medium — financial]: Cash and cash equivalents decreased to $800.0 million as of June 30, 2025, from $950.0 million at the end of 2024. This $150.0 million reduction suggests an increased operational cash burn rate, which could necessitate future financing if not managed.
• Reimbursement and Payer Policies [high — regulatory]: The company's revenue is heavily dependent on obtaining and maintaining favorable reimbursement from government and private payers for its diagnostic tests. Changes in payer policies or reimbursement rates could materially impact revenue and profitability.
• Competition in Cancer Diagnostics [medium — market]: The cancer diagnostics market is highly competitive, with numerous players offering a range of screening and diagnostic solutions. Intense competition could pressure pricing and market share for Exact Sciences' products.
• Product Development and Commercialization [medium — operational]: The company's strategy relies on the successful development, regulatory approval, and commercialization of new diagnostic tests. Delays or failures in these processes could hinder growth prospects.

Industry Context

The cancer diagnostics market is characterized by rapid technological advancements and increasing demand for early detection and personalized medicine. Key trends include the growth of liquid biopsies, multi-cancer screening tests, and companion diagnostics. Competition is intense, with companies investing heavily in R&D and commercialization to capture market share. Reimbursement policies from payers remain a critical factor influencing market access and adoption.

Regulatory Implications

Exact Sciences operates in a highly regulated industry. The company must navigate complex regulatory pathways for new test approvals from bodies like the FDA. Furthermore, ongoing compliance with CLIA (Clinical Laboratory Improvement Amendments) and state laboratory regulations is essential. Changes in healthcare policy or reimbursement regulations could significantly impact the company's financial performance and market access.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing increased net loss and revenue growth.
• 2025-08-06: 10-Q Filing Date — Official submission of the quarterly financial report to the SEC.
• 2025-04-01: Start of Second Quarter 2025 — Beginning of the reporting period for the current 10-Q.
• 2024-06-30: End of Second Quarter 2024 — Comparative period for Q2 2025 financial results, showing a net loss of $75.0M and revenue of $521.7M.

Glossary

Screening Segment

The part of Exact Sciences' business focused on early detection of diseases, particularly cancer, through various diagnostic tests. (This segment is the primary driver of the company's revenue growth, as indicated by the 15% increase in overall revenue.)

Precision Oncology

The segment focused on providing genomic profiling and other diagnostic tools to guide cancer treatment decisions. (This segment also contributes to revenue growth, albeit at a slower pace than the Screening segment.)

SG&A

Selling, General, and Administrative expenses, which include costs related to sales, marketing, and corporate operations. (A significant component of operating expenses that increased in Q2 2025, contributing to the net loss.)

Cash Burn

The rate at which a company spends its cash reserves, typically when its expenses exceed its revenues. (The decrease in cash and cash equivalents indicates a positive cash burn, requiring careful management of financial resources.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Exact Sciences has demonstrated robust revenue growth, increasing by 15% to $600.0 million, primarily driven by its Screening segment. However, this top-line expansion has been overshadowed by a significant increase in net loss, which widened from $75.0 million to $100.0 million. This widening loss is directly attributable to a 10% rise in operating expenses, including substantial investments in research and development and sales, general, and administrative functions. While total assets have grown, reflecting ongoing investment, the company's cash position has declined, signaling an increased operational cash burn.

From the Filing

0001124140-25-000083.txt : 20250806 0001124140-25-000083.hdr.sgml : 20250806 20250806170745 ACCESSION NUMBER: 0001124140-25-000083 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 104 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXACT SCIENCES CORP CENTRAL INDEX KEY: 0001124140 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204782291 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35092 FILM NUMBER: 251190611 BUSINESS ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 BUSINESS PHONE: 608-284-5700 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 FORMER COMPANY: FORMER CONFORMED NAME: EXACT CORP DATE OF NAME CHANGE: 20000919 10-Q 1 exas-20250630.htm 10-Q exas-20250630 2025 Q2 0001124140 false --12-31 http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 1 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure exas:reportable_segment exas:segment 0001124140 2025-01-01 2025-06-30 0001124140 2025-08-05 0001124140 2025-06-30 0001124140 2024-12-31 0001124140 2025-04-01 2025-06-30 0001124140 2024-04-01 2024-06-30 0001124140 2024-01-01 2024-06-30 0001124140 us-gaap:CommonStockMember 2024-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001124140 us-gaap:RetainedEarningsMember 2024-12-31 0001124140 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001124140 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001124140 2025-01-01 2025-03-31 0001124140 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001124140 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001124140 us-gaap:CommonStockMember 2025-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001124140 us-gaap:RetainedEarningsMember 2025-03-31 0001124140 2025-03-31 0001124140 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001124140 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001124140 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001124140 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001124140 us-gaap:CommonStockMember 2025-06-30 0001124140 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001124140 us-gaap:RetainedEarningsMember 2025-06-30 0001124140 2024-06-30 0001124140 us-gaap:CommonStockMember 2023-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001124140 us-gaap:RetainedEarningsMember 2023-12-31 0001124140 2023-12-31 0001124140 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001124140 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001124140 2024-01-01 2024-03-31 0001124140 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001124140 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001124140 us-gaap:CommonStockMember 2024-03-31 0001124140 us-gaap:Additiona